In April of this year, Sino Biotech and Sinopharm Capital's investment company Fo Nuo Jian jointly established CNBG-VIROGIN BIOTECH. Sino Biotech will give full play to the advantages of Sino Biotech and Fu Nuojian in R&D, clinical, production, sales and other fields, realize complementary advantages and collaborative innovation, and develop and introduce a new generation of oncolytic viruses, vector vaccines, and antibodies based on viral vectors. It has become a leader in the field of tumor immunotherapy in China and brought new dawn to the majority of tumor patients.

On August 26, Sinopharm’s invested company Fonogym successfully held a new scientific and clinical advisory committee meeting in Vancouver, Canada. The new scientific and clinical advisory committee has a strong lineup, including well-known scholars, professors and clinical experts. His professional background covers many fields such as oncolytic virus biology, tumor immunology, clinical oncology, oncolytic virus production and process optimization.

During the meeting, the experts focused on the clinical strategy and market prospects of VG161, and put forward valuable opinions and suggestions on the upcoming phase 1 clinical trial, involving clinical plan design, indication selection, inclusion criteria, clinical sample analysis, and risk Management and control and other aspects.

In this regard, Huang Hongwei, general manager of CNBG-VIROGIN, said: “We are committed to becoming the strongest oncolytic virus research and development and transformation platform in China. Oncolytic virus products including VG161 are launched to the market, bringing good news to the vast number of cancer patients in China."

Zhang Yuntao, Chairman of Biomedicine, expressed his warm congratulations on the successful convening of the conference, and asked the company's clinical team to strengthen the interaction with internationally renowned experts, earnestly do a good job in the clinical design and preparation of the company's first product VG161, and fully coordinate the use of China Various biological resources contribute to the development of Zhongsheng's innovative medicine field.

What is an oncolytic virus?

Oncolytic virus therapy is a new type of tumor treatment that kills tumors by selectively infecting tumor cells with viruses. Oncolytic virus is a kind of tumor-killing virus with replication ability. It can selectively infect tumor cells and replicate in tumor cells to kill tumor cells and stimulate the body to produce specific anti-tumor immune responses.

What is VG161?

VG161 uses the HSV-1 virus skeleton with greater oncolytic activity and carries multiple immune stimulating factors at the same time, which can synergistically activate the body's natural and adoptive anti-tumor immune function, in order to achieve significant persistence in clinically refractory tumors. The clinical anti-tumor effect.

On November 29, 2018, Sinopharm officially introduced the strategic investor Sinopharm Capital. All the shareholders of Sinopharm: Borun Investment, Gimpo Investment, Furong Qingyun Fund, PurityStar, etc., gathered in the Shanghai office of Sinopharm Capital to sign a new agreement. Company documents. Since then, Sinopharm Capital has assisted in the research and development of VG161 and other drugs such as Fonogym Biotech in various aspects such as process development and review.

About Virogin Biotech Ltd.

Virogin Biotech（ Virogin Biotech Ltd.下称“Virogin”）It is a tumor immunotherapy innovative drug research and development company. Because of the breakthrough in a new generation of oncolytic virus drugs carrying immunostimulatory factors, it has become a leader in the development of new technologies and new drugs in the field of tumor immunotherapy. Fonogym uses the world's first TTDR (transcription-translation dual regulation) oncolytic virus backbone platform, and uses this as a vector to integrate various antiviral immune regulatory factors, establish a unique Synerlytic oncolytic virus platform, and develop multiple anti-cancer platforms Oncolytic virus product pipeline.

About Sinopharm Capital

Sinopharm Capital Management Co., Ltd. is a professional equity investment institution initiated and established by Sinopharm Group to focus on the medical and health field. The management team is composed of professional investors inside and outside Sinopharm Group in accordance with the market mechanism. He has a deep understanding of the development of the medical and health industry, industrial operation and capital operation, and can effectively integrate the internal and external industry resources and capital strength of Sinopharm Group.

Sinopharm Capital adheres to the responsibilities and feelings of industrial capital, adhering to the corporate culture of "sincerity, professionalism, and win-win", and aspires to become the discoverer, excavator, integrator and realizer of the value of China's medical and health industry by focusing on industry segments Innovative and growth-oriented companies promote the development and management of the entire industry, become a provider of resource element integration solutions that match their development strategies for funded companies, and provide better and cheaper health services for the Chinese people.

Source: Sinopharm Capital

Disclaimer: Please contact us if it involves content, copyright or other issues.